Dorzolamide

證據等級: L5

預測適應症: 10 個

Dorzolamide: From Ocular Hypertension to Primary Hereditary Glaucoma

One-Sentence Summary

Dorzolamide is a topical carbonic anhydrase inhibitor (CAI) with established global use in reducing intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension, though it is currently not registered in the Philippines. The TxGNN model ranks Primary Hereditary Glaucoma as its top new indication (score 99.99%), supported by 1 completed Phase 2 clinical trial (n=37) directly evaluating Dorzolamide in pediatric hereditary glaucoma. Importantly, TxGNN also predicts strong efficacy for the broader Open-Angle Glaucoma spectrum (ranks 6–7), backed by Level 1 evidence from multiple Phase 3 RCTs and a Cochrane review — reflecting Dorzolamide’s well-established mechanistic rationale across all IOP-driven glaucoma subtypes.

Quick Overview

Item	Content
Original Indication	Ocular hypertension and open-angle glaucoma (global approvals; not registered in Philippines)
Predicted New Indication	Primary Hereditary Glaucoma
TxGNN Prediction Score	99.99%
Evidence Level	L2
Philippines Market Status	✗ Not marketed
Number of Registrations	0
Recommended Decision	Research Question

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the Philippines regulatory database. Based on established pharmacological knowledge, Dorzolamide is a sulfonamide-class carbonic anhydrase inhibitor. It selectively targets CA II and CA IV isoforms expressed in the ciliary epithelium of the eye. By blocking these enzymes, Dorzolamide reduces bicarbonate secretion into the posterior chamber, thereby decreasing aqueous humor production by approximately 17–20% — resulting in a clinically meaningful reduction in IOP. This mechanism has been validated across numerous Phase 3 and Phase 4 randomized controlled trials and underpins its regulatory approvals by the US FDA and EMA.

Primary hereditary glaucoma encompasses a group of genetic conditions — including mutations in MYOC and CYP1B1 — that cause abnormal anterior chamber angle development or trabecular meshwork dysfunction, ultimately leading to elevated IOP and progressive optic nerve damage. Because Dorzolamide reduces IOP through aqueous humor suppression (a complementary pathway independent of drainage), it offers a mechanistically rational symptomatic therapy even when the underlying genetic defect remains unaddressed. This is analogous to how Dorzolamide is used as adjunctive treatment in surgically refractory adult glaucoma.

One important caveat: medication responsiveness in congenital or hereditary glaucoma subtypes (particularly primary congenital glaucoma) may differ from adult open-angle glaucoma, where surgical intervention is often the first-line approach. The available Phase 2 trial (NCT01527682) was specifically designed for pediatric hereditary glaucoma refractory to surgery, providing direct — if limited — evidence for this specific TxGNN prediction.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01527682	Phase 2	Completed	37	Evaluated ocular hypotensive effects of latanoprost (prostaglandin analogue) vs. dorzolamide (CAI) in pediatric glaucoma refractory to surgical procedures, including primary hereditary subtypes; assessed both efficacy and safety over an extended follow-up period through November 2016

Literature Evidence

Currently no related literature directly addressing Primary Hereditary Glaucoma is available.

Additional Context: Open-Angle Glaucoma Evidence (Ranks 6–7)

TxGNN simultaneously predicts strong efficacy for Glaucoma 1, Open Angle and Open-Angle Glaucoma (ranks 6–7, scores ~99.75–99.70%), which share the same IOP-lowering mechanism and carry Level 1 evidence. Key supporting trials and literature are summarized below for reference.

Selected Phase 3 Clinical Trials for Open-Angle Glaucoma

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00333125	Phase 3	Completed	319	Directly compared IOP-lowering efficacy and safety of two combination glaucoma therapies including dorzolamide in open-angle glaucoma or ocular hypertension; highest-grade direct evidence
NCT00546286	Phase 3	Completed	170	Evaluated dorzolamide-timolol (Cosopt®) as first-line therapy in previously untreated open-angle glaucoma and ocular hypertension over 12 weeks
NCT00108017	Phase 3	Completed	330	Multicenter double-masked parallel study evaluating 24-hour diurnal IOP control with dorzolamide 2%/timolol 0.5% vs. comparator in open-angle glaucoma and ocular hypertension
NCT05973305	Phase 3	Completed	118	Randomized open-label comparative efficacy/safety study of generic dorzolamide 20 mg/mL vs. Trusopt® (reference) in POAG patients
NCT05973318	Phase 3	Completed	110	Randomized controlled non-inferiority study of generic dorzolamide/timolol combination vs. Cosopt® in POAG patients
NCT02053298	Phase 4	Completed	30	Mechanistic study on the impact of timolol/dorzolamide therapy on vascular autoregulation in glaucoma patients; important hemodynamic supplementary data
NCT00675207	Phase 4	Completed	120	Head-to-head comparison of dorzolamide 2% vs. brimonidine and brinzolamide as adjunctive therapy to prostaglandin analogues in glaucoma and ocular hypertension
NCT01471158	Phase 4	Completed	120	Patient preference study comparing AZARGA® vs. COSOPT® (dorzolamide/timolol) in open-angle glaucoma and ocular hypertension
NCT00545064	Phase 4	Completed	176	Multicenter open-label study evaluating tolerability of preservative-free dorzolamide-timolol in open-angle glaucoma patients with dry eyes; real-world tolerability data
NCT00972257	Phase 4	Completed	64	First crossover comparison of 24-hour IOP control quality between dorzolamide/timolol and brimonidine/timolol fixed combinations in POAG

Selected Literature for Open-Angle Glaucoma

PMID	Year	Type	Journal	Key Findings
17943780	2007	Cochrane Review	Cochrane Database Syst Rev	Systematic review of medical interventions for POAG and ocular hypertension; establishes evidence base for CAI therapy including dorzolamide
26526633	2016	Systematic Review	Ophthalmology	Network meta-analysis comparing first-line medications for POAG; provides relative efficacy rankings including dorzolamide-containing regimens
39677168	2024	RCT	Cureus	Phase 3 RCT comparing brinzolamide/timolol vs. dorzolamide/timolol fixed combinations in Indian POAG patients; recent real-world efficacy data from Asia
39569785	2024	RCT	Vestnik Oftalmologii	Efficacy and safety evaluation of dorzolamide/timolol (Dorzotimol) fixed combination in POAG in real-world clinical settings
34447609	2021	RCT	J Drug Assess	Compared therapeutic efficacy/safety of dorzolamide/timolol fixed combination dosed TID vs. BID in newly diagnosed POAG
37425383	2023	Cohort Study	Malays J Med Sci	Assessed IOP-lowering and adherence between fixed vs. non-fixed dorzolamide/timolol combinations in OAG patients at a Malaysian hospital; relevant Southeast Asian real-world data
17154662	2006	Review	Drugs Aging	Comprehensive review of dorzolamide 2%/timolol 0.5% (Cosopt®) use in glaucoma and ocular hypertension; covers mechanism, efficacy, and safety profile
36453306	2022	Clinical Study	Indian J Ophthalmol	Indian carbonic anhydrase inhibitor trial demonstrating dorzolamide 2% efficacy in improving retrobulbar ocular blood flow in OAG patients
21220628	2011	Mechanistic Study	Arch Ophthalmol	Investigated antioxidant/mitochondria-targeting effects of dorzolamide and timolol; supports additional neuroprotective mechanism beyond IOP reduction
40261315	2025	Review/Guideline	Med Lett Drugs Ther	Current treatment guideline overview for open-angle glaucoma drugs, including dorzolamide’s role in contemporary management

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Research Question (for Primary Hereditary Glaucoma specifically)

Rationale: One completed Phase 2 trial (n=37) provides preliminary evidence that Dorzolamide can reduce IOP in pediatric hereditary glaucoma refractory to surgery, and the mechanistic link is biologically sound. However, the small sample size and single-trial evidence base are insufficient to advance beyond a research question at this stage.

Important strategic note: For the Open-Angle Glaucoma spectrum (TxGNN ranks 6–7), evidence is at Level 1 with multiple completed Phase 3 RCTs. In this context, the recommended decision is Proceed with Guardrails — and the priority action for the Philippines should be initiating a regulatory registration application, as Dorzolamide is a globally established first- and second-line glaucoma therapy with no Philippines registration to date.

To proceed, the following is needed:

Philippines registration pathway: Submit a registration dossier to the Philippine FDA (FDA Philippines) for Dorzolamide ophthalmic solution (2%), leveraging existing global Phase 3 data and the FDA Philippines reliance framework for already-approved drugs
Mechanism of action documentation: Obtain full DrugBank MOA data (CA II/IV inhibition) to complete the mechanistic analysis (Data Gap DG002)
Local safety review: Download and parse the prescribing information/package insert (Data Gap DG001) to complete contraindication and warning assessment
Pediatric glaucoma research: For the primary hereditary glaucoma indication specifically, a local or regional Phase 2/3 pediatric study is needed to generate Philippines-relevant efficacy and safety data
Database correction: Update the Philippines regulatory database to reflect that Dorzolamide’s open-angle glaucoma indication has L1 global evidence, enabling prioritization of registration submission

⚠️ Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before application. All treatment decisions should be made by qualified healthcare professionals in accordance with local regulatory approvals.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.